Keurig Dr Pepper Soars; Carter's Falls; Avidity Biosciences Rallies
Affected assets and topics
Why it matters
Keurig Dr Pepper's shares surged due to revised sales growth expectations and a $7 billion funding deal, while Carter's shares fell after missing sales estimates and announcing job cuts and store closures. Avidity Biosciences' shares rallied after being acquired by Novartis for $12 billion.
Article tone
Expected market reaction
Market impact analysis based on bullish sentiment with 85% confidence.
Evidence trail
Evidence
AI provenance
Technical identifiers
- Provider tag
- groq-llama-3.1-8b-instant
- Analysis version
- groq-llama-3.1-8b-instant
- Article id
- 2930
Original source
On this episode of Stock Movers with Lisa Mateo: - Keurig Dr Pepper (KDP) shares soared ahead of the New York open after the company announced it now expects fiscal 2025 constant currency net sales growth in a high-single-digit range, revised from a mid-single-digit growth outlook previously. KDP also announced it is raising $7 billion from Apollo and KKR to help finance its acquisition of JDE Peet’s NV, aiming to ease investor concerns about taking on too much debt. - Carter's (CRI) shares fall ahead of the open after the children’s apparel company reported net sales for the third quarter that missed the average analyst estimate. The company also plans to reduce offices-based roles by about 15% by the end of 2025, and it boosted the amount of stores it plans to close. - Avidity Biosciences (RNA) shares rally in premarket trading after Novartis (NOVN) agreed to buy the biotechnology company in a deal valued at $12 billion. (Source: Bloomberg)
Read the full article on Bloomberg
Original article published by Bloomberg on October 27, 2025. Analysis and insights provided by AnalystMarkets AI.